SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-207863
Filing Date
2022-08-01
Accepted
2022-08-01 09:15:58
Documents
15
Period of Report
2022-07-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d387414d8k.htm   iXBRL 8-K 29080
2 EX-99.1 d387414dex991.htm EX-99.1 23947
7 GRAPHIC g387414sp002.jpg GRAPHIC 9910
  Complete submission text file 0001193125-22-207863.txt   249266

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apgn-20220729.xsd EX-101.SCH 3176
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE apgn-20220729_def.xml EX-101.DEF 16129
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apgn-20220729_lab.xml EX-101.LAB 26531
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apgn-20220729_pre.xml EX-101.PRE 16843
9 EXTRACTED XBRL INSTANCE DOCUMENT d387414d8k_htm.xml XML 7228
Mailing Address 280 PARK AVENUE, SUITE 43W NEW YORK NY 10017
Business Address 280 PARK AVENUE, SUITE 43W NEW YORK NY 10017 6466036716
Brookline Capital Acquisition Corp. (Filer) CIK: 0001814140 (see all company filings)

IRS No.: 851260244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39488 | Film No.: 221123035
SIC: 2834 Pharmaceutical Preparations